Project

Control and Prevention of Tuberculosis (CAP-TB)

FHI 360’s Control and Prevention of Tuberculosis (CAP-TB) project aims to reduce the incidence and mortality of multidrug-resistant TB (MDR-TB) in China, Laos, Myanmar (Burma), Papua New Guinea and Thailand. Under this project, FHI 360 partners with national TB programs and stakeholders to develop and implement a strategic model for MDR-TB management that will enable countries to move toward eliminating this disease. The project, funded by the U.S. Agency for International Development (USAID), serves as a regional leader for developing active drug safety systems to support patients who are on new TB drugs and regimens. This is a critical priority given the growing use of bedaquiline, the first new drug in more than 40 years that treats TB.

The CAP-TB model:

  • Strengthens health systems by building expertise in MDR-TB management that is patient-centered and community-driven
  • Changes traditional norms for patient-provider communication
  • Uses social media to create virtual communities that support patients
  • Develops technology that uses data to improve the management of patients with MDR-TB

The CAP-TB project was profiled in October 2016 at the 47th World Conference on Lung Health in Liverpool, United Kingdom, through the conference’s thought leadership series. This short film highlights CAP-TB’s work in Yunnan Province, China.

Follow this project on Facebook and Twitter.

Countries:
  • Asia Pacific Regional Office
  • China
  • Laos
  • Myanmar (Burma)
  • Papua New Guinea
  • Thailand
Funder: USAID/Regional Development Mission for Asia (USAID/RDMA)
Duration: 2011 - 2017
URL: CAP-TB